PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy

<sup>177</sup>Lu-Prostate-specific membrane antigen (PSMA)-radioligand therapy (RLT) is a promising treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC). We aimed to determine the predictive value of pretherapeutic PSMA-ligand positron emission tomogr...

Full description

Bibliographic Details
Main Authors: Liam Widjaja, Rudolf A. Werner, Tobias L. Ross, Frank M. Bengel, Thorsten Derlin
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
prostate carcinoma
PSMA
radioligand therapy
PET/CT
biochemical response
mCRPC
Online Access:https://www.mdpi.com/2072-6694/13/12/2938

Internet

https://www.mdpi.com/2072-6694/13/12/2938

Similar Items